The Short Form Qualiveen (SF-Qualiveen) is an 8-item version of the Qualiveen questionnaire used to evaluate the impact of urinary symptoms on the quality of life in patients with urological dysfunction due to neurological disorders. The questionnaire was never available in the Russian language before. The study is aimed at providing the translation, cultural adaptation, and validation of a Russian version of the SF-Qualiveen for the use in patients with multiple sclerosis (MS). Materials and Methods. The original English language version of the SF-Qualiveen was translated into Russian according to the cultural and linguistic adaptation algorithm. The participants (50 MS patients with neurogenic bladder and 10 relatively healthy volunteers) filled out the finalized Russian version of the SF-Qualiveen and the Neurogenic Bladder Symptom Score (NBSS) twice, 2 weeks apart. The data obtained was used to determine the internal consistency (Cronbach’s alpha), external validity (the Spearman correlation), and test-retest reliability (intraclass correlation coefficient (ICC)) of the questionnaire. Results. The mean SF-Qualiveen total score was 2.51±0.79 in patients with a neurogenic bladder and 0.1±0.02 in the control group (p<0.001). Cronbach’s alpha exceeded 0.9 indicating an excellent internal consistency of the questionnaire. The retest did not reveal any significant differences between the findings. The test-retest reliability was good for all items and domains (ICC 0.81-0.89). The total score demonstrated the highest ICC (0.89). The external validity was verified by a strong correlation demonstrated between the SF-Qualiveen and NBSS scores. Conclusions. The Russian SF-Qualiveen questionnaire is a reliable, valid, and consistent tool for the assessment of a urinary disorder impact on the quality of life in patients with MS.
Aims: To evaluate the practical relevance of changes in serum and urinary neurotrophins levels in patients with multiple sclerosis (MS) and neurogenic lower urinary tract dysfunction (NLUTD) after intradetrusor injections of botulinum toxin A (BoNTA). Methods: The study included 36 patients with MS and NLUTD and 20 controls. The patients with NLUTD received intradetrusor injection of BoNTA (200 U). The nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) levels were measured in serum and urine at baseline and then at 1, 3, and 6 months by enzyme-linked immunosorbent assay. Urinary NGF and BDNF were normalized to creatinine (NGF/Cr, BDNF/Cr). Patients' assessment included urodynamic examination and Neurogenic Bladder Symptom Score (NBSS). Results: After BoNTA injections, no significant changes were observed in the serum NGF and BDNF or the urinary BDNF/Cr. The urinary NGF/Cr was significantly higher in MS patients (1.23 ± 0.34) at baseline compared with controls (0.084 ± 0.02; p = .021). The urinary NGF/Cr decreased to 0.51 ± 0.12 (p = .001) and 0.53 ± 0.32 (p = .005) at 1 and 3 months, increasing to 1.12 ± 0.49 (p = .003) at 6 months. The urinary NGF/Cr level at baseline demonstrated a low diagnostic accuracy in predicting a better response to the BoNTA treatment (area under the curve = 0.661; p = .047) and no correlation with the urodynamic parameters. Conclusions: The urinary NGF/Cr at baseline or its reduction at the first month following treatment does not serve as a predictor for the response to the BoNTA injections or for urodynamic changes.
Введение. Реорганизация микробиома мочи больных нейрогенным мочевым пузырем играет важную роль в патогенезе инфекции мочевыводящих путей (ИМп). сведения о составе мочевого микробиома при нейрогенной дисфункции нижних мочевыводящих путей (НДНМп) ограничены, в частности, неизвестно, как на него влияют различные виды терапии НДНМп. Цель исследования. Оценить влияние инъекций ботулинического токсина на микробиом мочи больных НДНМп. Материалы и методы. Образцы мочи были взяты у шести пациентов с НДНМп (четырёх женщин и двух мужчин) до введения 200 ЕД ботулинического токсина типа А в стенку мочевого пузыря и через 6 недель после. Образцы исследовали методом микроскопии, выполняли посев на микробиологические среды, а также метагеномное 16S рРНК секвенирование. с использованием платформы Illumina MiSeq получено, в общей сложности, 144 562 16S рДНК прочтений. Результаты. Результаты посевов мочи коррелировали с данными 16S рРНК секвенирования, однако анализ метагенома позволил выявить и идентифицировать большее количество микроорганизмов. В каждом образце выделено от 2 до 21 рода микроорганизмов. В моче всех больных до ботулинотерапии преобладали Enterobacterales. после ботулинотерапии у трех пациенток, на фоне клинического и уродинамического улучшения, произошла смена микрофлоры с преобладанием Enterobacterales на Lactobacillales. В остальных случаях принципиальных изменений микробиома отмечено не было. Заключение. Впервые в рамках пилотного исследование проведено сравнение микробиома мочи у больных НДНМп до и после введения ботулинического токсина. Небольшое число участников является существенным ограничением данной работы, однако продемонстрирована возможность положительного влияния ботулинотерапии на микрофлору мочевыводящих путей. Ключевые слова: нейрогенный мочевой пузырь; инфекция мочевыводящих путей; микробиом мочи; ботулинический токсин Финансирование. Исследование не имело спонсорской поддержки. Конфликт интересов. Авторы заявляют об отсутствии конфликта интересов. Информированное согласие. Все пациенты подписали информированное согласие на участие в исследовании. Вклад авторов: Екатерина с. Филиппова-идея исследования, сбор материала, обработка данных, написание текста статьи; Игорь В. Баженов-организация исследования, сбор материала, редактирование текста статьи; Александр В. Зырянов-разработка дизайна исследования, финальное редактирование.
Most modern pet species have awide breed variability. The genetic aspect plays a signif-icant role in the development of individual pathologies. A retrogen encoding fibroblast growth factor 4 (FGF4), when inserted into the chromosome 18of dogs (CFA18), leads to chondrodysplasia, phenotypically mani-festing itself as shortened limbs in dogs. The incorporation of the FGF4 retrogene into chromosome 12 (CFA12) leads to a similar phenotype, but associated with an increased degeneration of the intervertebral discs. Although many retrogens are considered “silent”pseudogenes, the FGF4 retrogene in cases of chondrodysplasia and chondro-dystrophy is transcriptionally activated and leads to hyperactivation of the fi-broblast growth factor 3 receptor (FGFR3). Mutations are dominant, but links with spinal problems have been identified only for one, where the retro-gene is integrated into chromosome 12. Thus, dogs with the phenotype of short limbs are at risk for degenerative disease of the intervertebral discs, however, the disease recorded among animals is not related to chondrodystrophoids. The genetic predispo-sition of dogs of chondrodystrophoid breeds to degeneration of intervertebral discs is not a pathognomonic criterion for its presence. The study included genetic tests of dogs of different breeds, which were examined for compression myelopathy as a result of degeneration of the intervertebral discs. During testing, the purpose of which was to find correlation, the corresponding pedigree predispositions and clinical mani-festations of degenerative diseases of the intervertebral discs among 20 dogs (14 chondrodystrophoid and 6 non-chondrodystrophoid) wereconfirmed, in 14 cases (i.e. 70%) discogenic compres-sion was revealed during tomography.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.